Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Re-appointment of Cost Auditors of the Company
Regulatory Filings Classification · 65% confidence The document is a formal SEBI‐mandated disclosure to stock exchanges detailing the outcome of the Board of Directors meeting (approval of business transfer agreement addendum, approval of audited results, dividend recommendation, auditor reappointment) along with the declaration under Regulation 33 and the independent auditor’s report. It is not a full annual report (10-K), nor is it simply an earnings highlights press release (ER), interim report (IR) or management change notice (MANG). It is a regulatory compliance filing under India’s Listing Obligations and Disclosure Requirements that does not neatly fit another specific category, making Regulatory Filings (RNS) the appropriate classification.
2026-05-26 English
Please find attached the file
Earnings Release Classification · 75% confidence The document is a formal stock-exchange filing under SEBI Listing Regulations reporting the outcome of a Board meeting, which includes the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This constitutes the company’s earnings release rather than a full annual report or an interim/quarterly report document. It is not merely a certification or publication notice but the actual announcement of financial results. Hence it best fits the Earnings Release category (ER). FY 2026
2026-05-26 English
Please find attached the file
Regulatory Filings Classification · 80% confidence The document is a formal exchange filing to the NSE and BSE dated May 26, 2026 announcing the outcome of the Board of Directors meeting. It includes approval of a business transfer agreement addendum, audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026 (with the auditors’ unmodified opinion), recommendation of a final dividend, and auditor appointment. This is not the full Annual Report (10-K) nor a brief earnings highlight (ER), nor is it a standalone Audit Report (AR) or capital/financing update. Instead, it is a regulatory announcement of board resolutions and financial results under SEBI Listing Regulations—a miscellaneous compliance filing. Therefore, it best fits the Regulatory Filings (RNS) category.
2026-05-26 English
Please find attached the file
Audit Report / Information Classification · 85% confidence The document is a Stock Exchange filing under SEBI listing regulations announcing the outcome of a Board of Directors meeting and encloses the Auditors’ Report on the standalone and consolidated financial results (unmodified opinion, basis for opinion, management responsibilities, etc.). It is not an earnings teaser or investor presentation but a standalone audit report/information on the quarterly and year-end financial statements. Therefore it falls under Audit Report / Information (AR).
2026-05-26 English
Appointment
Earnings Release Classification · 85% confidence The document is the formal stock exchange submission of the Board’s meeting outcome, including approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditors’ report. This is not a full Annual Report (10-K) or MD&A, but the initial, regulated announcement of financial results under SEBI Listing Regulations. It therefore best matches an Earnings Release (initial announcement of periodical financial results). FY 2026
2026-05-26 English
Dividend
Earnings Release Classification · 70% confidence The document is a formal board meeting outcome filed with the stock exchanges (NSE & BSE) under SEBI Listing Regulations, containing the audited quarterly and year‐end financial results and auditor’s report (Regulation 33). It is not a full Annual Report (10-K), nor a proxy, M&A, or ESG report. It is the initial regulatory announcement of the company’s financial results for the quarter and fiscal year ended March 31, 2026, which corresponds to an Earnings Release. FY 2026
2026-05-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.